Dr. Koen Vandenbroeck, director of Neurogenomiks (UPV/EHU-Ikerbasque) is leading a European research project on personalised medicine for the treatment of multiple sclerosis, which has received 2.36 million euros in funding.

Neurogenomiks is coordinating the work of a consortium made up of nine teams from different countries such as Spain, France, Germany, Netherlands and Russia, in which the Basque biotech company Progenika Biopharma, which specialises in the development and manufacture of DNA chips to diagnose illnesses, is also taking part.

The consortium is part of the UEPHA*MS (United Europeans for the development of PHArmacogenomics in Multiple Sclerosis) network, which met in Bilbao on 10, 11 and 12 June to take part in a Workshop on biostatistics applied to multiple sclerosis.

The Neurogenomiks laboratory was inaugurated on 18 March last in the Bizkaia Technology Park and focuses part of its research work on the search for therapies to treat multiple sclerosis, a chronic neurological disease that currently affects 400,000 patients in Europe (2,000 in the Basque Country) and for which no definitive cure yet exists.